Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SC01009 Menstrual Blood-Derived MSCs in Idiopathic Pulmonary Fibrosis (Phase II)
ChiCTR2500108993Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Sep 2025
- Modality
- Stem Cell Therapies → Cell Therapies
- Countries
- 1
01
Overview
Phase 2, randomised trial in idiopathic pulmonary fibrosis (IPF) comparing SC01009 at week 1 and week 13, SC01009 at week 1 then placebo at week 13 and Placebo at week 1 and week 13 (3 arms). Primary endpoint: Forced vital capacity (FVC) at 24 weeks. Started Sep 2025; status: recruiting.
02
Drugs
SC01009
03
Conditions
idiopathic pulmonary fibrosis (IPF)
Beyond the preview
Go deeper on ChiCTR2500108993.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2500108993.